We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Live webcast on Wednesday, May 1st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation Continued advancement of an innovative pipeline of NKT cell...
LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024...
Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing...
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases Ongoing efforts to build a robust global patent estate for a...
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0867 | -16.7763157895 | 0.5168 | 0.5299 | 0.4115 | 147948 | 0.4503195 | CS |
| 4 | -0.3459 | -44.574742268 | 0.776 | 0.7805 | 0.4115 | 141914 | 0.52185739 | CS |
| 12 | -0.9199 | -68.1407407407 | 1.35 | 1.62 | 0.4115 | 351882 | 0.86915416 | CS |
| 26 | -7.8999 | -94.8367346939 | 8.33 | 10.36 | 0.4115 | 606123 | 2.59956027 | CS |
| 52 | -46.8899 | -99.0910819949 | 47.32 | 62.2314 | 0.4115 | 341532 | 3.87095604 | CS |
| 156 | -91.9699 | -99.5345238095 | 92.4 | 93.31 | 0.4115 | 337469 | 4.26408847 | CS |
| 260 | -91.9699 | -99.5345238095 | 92.4 | 93.31 | 0.4115 | 337469 | 4.26408847 | CS |
Monksdream
2 months ago
littleharoldeh
2 months ago
tw0122
2 months ago
Monksdream
2 months ago
Monksdream
3 months ago
Invest-in-America
3 months ago
Awl416
3 months ago
IVANj
3 months ago
TheFinalCD
3 months ago
Renee
3 months ago
KOGT
6 months ago
Monksdream
7 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
